Policy Solutions to the Opioid Crisis: What Have We Learned?

Activity Details
  • Credit Amounts:
    • CME: 0.75
    • CPE: 0.75
    • CNE: 0.75
    • Other: 0.75
    • CDE: 0.75
    • CPHCE: 1.00
  • Cost: Free
  • Release: May 16, 2023
  • Expires: May 15, 2026
  • Estimated Time to Complete:
    45 Minutes
  • Average User Rating:
    (24 Ratings)

Faculty

Jeffery Talbert Jeffery Talbert, PhD
Joseph Schutte Professor, Pharmaceutical Policy, Pharmacy Practice and Science
Director, Institute for Pharmaceutical Outcomes and Policy
University of Kentucky College of Pharmacy
Division Chief, Biomedical Informatics
University of Kentucky College of Medicine
Associate Director
UK Center for Clinical and Translational Science
UK HealthCare
Deputy Director
Center for Rural and Underserved Health Research
Co-director, Data Analytics Core
Kentucky Can HEAL Project
Lexington, Kentucky

Needs Statement

Opioid use disorder is an ongoing epidemic and states are enacting a range of policies to address the crisis. Health care providers need to understand how the policies impact practice and patient outcomes.

Target Audience

Health care professionals/prescribers including physicians, physician assistants, nurses, advance practice registered nurses, pharmacists, dentists, dental hygienists, social workers, counselors, and any others interested in the prevention of and treatment for substance abuse disorder and sustained recovery.

Objectives

Upon completion of this activity, participants will be able to:

  • Describe supply-side and demand-side interventions used in substance use policy responses
  • Discuss recent policy changes in Kentucky that regulate the prescribing and dispensing of prescription opioids
  • Identify impact of policy changes on supply and demand for prescription opioids

Accreditation

In support of improving patient care, this activity has been planned and implemented by UK HealthCare CECentral and Kentucky Office of Drug Control Policy. University of Kentucky HealthCare CECentral is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

CME
This enduring material is designated for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

This training has been approved by the KBML as meeting the statutory requirements of HB1. 0619-H6.0-CEPK1

CPE
This knowledge-based activity will award 0.75 contact hours (0.075 CEUs) of continuing pharmacy education credit in states that recognize ACPE providers.

CNE
The University of Kentucky, College of Nursing is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).

This educational activity is offered for a maximum of 0.75 ANCC contact hours.

Provider #: 0040. In order to receive credit, participants complete this CNE activity and submit a credit application and evaluation form online. Certificates may be printed once the evaluation is completed.

Other
UK Healthcare CECentral certifies this activity for 0.75 hours of participation.

CDE
This online course meets regulatory requirements for 0.75 hours credit as permitted by 201 KAR 8:532 for dentists and 201 KAR 8:562 for dental hygienists.

CPHCE
University of Kentucky College of Public Health certifies that this educational activity was designated for 1.00 hour of Public Health Continuing Education (CPHCE) credit. This course is approved for continuing education by the University of Kentucky College of Public Health. ()

Faculty Disclosure

No speakers or planners have any relevant financial relationships to disclose.

The material presented in this course represents information obtained from the scientific literature as well as the clinical experiences of the speaker. In some cases, presentations might include discussion of investigational agents and/or off-label indications for various agents used in clinical practice. The speaker will inform the audience when discussing investigational and/or off-label uses.

Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Acknowledgement

This activity is jointly provided by the University of Kentucky and Kentucky Office of Drug Control Policy.

In collaboration with Kentucky Injury Prevention and Research Center (KIPRC).

Review Dates

7/9/22.